摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-苄氧基-2-巯基苯并咪唑 | 465546-82-1

中文名称
5-苄氧基-2-巯基苯并咪唑
中文别名
——
英文名称
5-(benzyloxy)-2-mercaptobenzimidazole
英文别名
5-(benzyloxy)-1H-benzo[d]imidazole-2-thiol;5-Benzyloxy-2-mercaptobenzimidazole;5-phenylmethoxy-1,3-dihydrobenzimidazole-2-thione
5-苄氧基-2-巯基苯并咪唑化学式
CAS
465546-82-1
化学式
C14H12N2OS
mdl
——
分子量
256.328
InChiKey
URZVNGKRWWMOKB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    228-230°C
  • 溶解度:
    少许溶于甲醇

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    65.4
  • 氢给体数:
    2
  • 氢受体数:
    2

SDS

SDS:74a2c787674d37b0210bf613b12c3e7d
查看

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Syntheses and pharmacokinetic evaluations of four metabolites of 2-(4-(2-((1H-benzo[d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)-N-(6-methyl-2,4-bis-(methylthio)pyridin-3-yl)acetamide hydrochloride [K-604], an acyl-CoA:cholesterol O-acyltransferase-1 inhibitor
    摘要:
    We synthesized and identified four metabolites of acyl-coenzyme A:cholesterol O-acyltransferase (ACAT)-1 inhibitor, K-604 (1). Two of the metabolites M1 and M2, were prepared from 1 using a combination reagent of hydrogen peroxide and sodium tungstate with either phosphoric acid or trifluoroethanol as the solvent to control the regioselectivity. Upon exposure of 4b to tert-butyl hypochlorite at -78 degrees C, the monosulfoxidation afforded synthetic intermediate of M3 in excellent yield. The efficient synthesis of M4 was established. The in vitro metabolic study exhibited a high clearance value (720 mu L/min/mg protein) of 1 using human liver microsomes. We orally administered a single dose of 10 mg/kg of 1 to monkeys because the in vitro metabolic patterns are quite similar. Fortunately, the drug concentration of 1 was much higher than those of M1, M2, M3 and M4.
    DOI:
    10.1016/j.bmc.2020.115457
  • 作为产物:
    描述:
    溴甲苯盐酸potassium carbonate溶剂黄146 作用下, 以 乙醇丙酮 为溶剂, 反应 26.0h, 生成 5-苄氧基-2-巯基苯并咪唑
    参考文献:
    名称:
    Syntheses and pharmacokinetic evaluations of four metabolites of 2-(4-(2-((1H-benzo[d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)-N-(6-methyl-2,4-bis-(methylthio)pyridin-3-yl)acetamide hydrochloride [K-604], an acyl-CoA:cholesterol O-acyltransferase-1 inhibitor
    摘要:
    We synthesized and identified four metabolites of acyl-coenzyme A:cholesterol O-acyltransferase (ACAT)-1 inhibitor, K-604 (1). Two of the metabolites M1 and M2, were prepared from 1 using a combination reagent of hydrogen peroxide and sodium tungstate with either phosphoric acid or trifluoroethanol as the solvent to control the regioselectivity. Upon exposure of 4b to tert-butyl hypochlorite at -78 degrees C, the monosulfoxidation afforded synthetic intermediate of M3 in excellent yield. The efficient synthesis of M4 was established. The in vitro metabolic study exhibited a high clearance value (720 mu L/min/mg protein) of 1 using human liver microsomes. We orally administered a single dose of 10 mg/kg of 1 to monkeys because the in vitro metabolic patterns are quite similar. Fortunately, the drug concentration of 1 was much higher than those of M1, M2, M3 and M4.
    DOI:
    10.1016/j.bmc.2020.115457
点击查看最新优质反应信息

文献信息

  • Novel cyclic diamine compounds and medicine containing the same
    申请人:Kowa Company, Ltd.
    公开号:US20040038987A1
    公开(公告)日:2004-02-26
    The present invention offers novel cyclic diamine compounds and a pharmaceutical composition containing the same. The present invention relates to a compound represented by the formula (I) or salt(s) or solvate(s) thereof. 1 (In the formula, 2 is an optionally substituted divalent residue of benzene, pyridine, cyclohexane or naphthalene or is a vinylene group where Ar is an optionally substituted aryl group; X is —NH—, oxygen atom or sulfur atom; Y is —NR 1 —, oxygen atom, sulfur atom, sulfoxide or sulfone; Z is a single bond or —NR 2 —; R 1 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; R 2 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; l is an integer of from 0 to 15; m is an integer of 2 or 3; and n is an integer of from 0 to 3). The compound of the present invention is useful as a pharmaceutical composition, particuarly as an inhibitor of acyl coenzyme A cholesterol acyltransferase (ACAT).
    本发明提供了新颖的环状二胺化合物以及含有该化合物的药物组合物。本发明涉及由式(I)表示的化合物或其盐或溶剂化合物。(在该式中,2是苯、吡啶、环己烷或萘的可选择取代的二价残基,或者是Ar为可选择取代芳基的乙烯基;X为—NH—、氧原子或硫原子;Y为—NR1—、氧原子、硫原子、亚砜或砜;Z为单键或—NR2—;R1为氢原子、可选择取代的较低烷基、可选择取代的芳基或可选择取代的硅烷较低烷基;R2为氢原子、可选择取代的较低烷基、可选择取代的芳基或可选择取代的硅烷较低烷基;l为0到15的整数;m为2或3的整数;n为0到3的整数)。本发明的化合物可用作药物组合物,特别是作为酰辅酶A胆固醇酰基转移酶(ACAT)的抑制剂。
  • Cyclic diamine compounds and medicine containing the same
    申请人:Shibuya Kimiyuki
    公开号:US06969711B2
    公开(公告)日:2005-11-29
    The present invention offers novel cyclic diamine compounds and a pharmaceutical composition containing the same. The present invention relates to a compound represented by the formula (I) or salt(s) or solvate(s) thereof. (In the formula, is an optionally substituted divalent residue of benzene, pyridine, cyclohexane or naphthalene or is a vinylene group where Ar is an optionally substituted aryl group; X is —NH—, oxygen atom or sulfur atom; Y is —NR 1 —, oxygen atom, sulfur atom, sulfoxide or sulfone; Z is a single bond or —NR 2 —; R 1 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; R 2 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; l is an integer of from 0 to 15; m is an integer of 2 or 3; and n is an integer of from 0 to 3). The compound of the present invention is useful as a pharmaceutical composition, particuarly as an inhibitor of acyl coenzyme A cholesterol acyltransferase (ACAT).
    本发明提供了新颖的环状二胺化合物以及含有该化合物的药物组合物。本发明涉及一种由式(I)表示的化合物或其盐或溶剂化合物。(在该式中,是苯、吡啶、环己烷或萘的可选择取代的二价残基,或者是一种乙烯基团,其中Ar是可选择取代的芳基;X是—NH—、氧原子或硫原子;Y是—NR1—、氧原子、硫原子、亚氧化物或砜;Z是单键或—NR2—;R1是氢原子、可选择取代的较低烷基团、可选择取代的芳基或可选择取代的硅烷较低烷基团;R2是氢原子、可选择取代的较低烷基团、可选择取代的芳基或可选择取代的硅烷较低烷基团;l是0到15的整数;m是2或3的整数;n是0到3的整数)。本发明的化合物可用作药物组合物,特别是作为酰辅酶A胆固醇酰基转移酶(ACAT)的抑制剂。
  • Method for producing cyclic diamine derivative or salt thereof
    申请人:Shibuya Kimiyuki
    公开号:US20060293519A1
    公开(公告)日:2006-12-28
    The present invention is directed to a method for producing a cyclic diamine compound (3) or a salt thereof through the following scheme: (wherein Ar represents a phenyl group, a pyridyl group, or a pyrimidinyl group, any of which may have a substituent; X represents NH, S, or O; ring A represents a benzene ring or a pyridine ring, which may have a substituent; 1 represents an integer of 1 or 2; m represents an integer of 1 or 2; and n represents an integer of 1 to 6). The method enables synthesis of a cyclic diamine compound (3) or a salt thereof, which serves as an ACAT inhibitor, in an industrially useful manner.
    本发明涉及通过以下方案制备环状二胺化合物(3)或其盐的方法:(其中Ar代表苯基、吡啶基或嘧啶基,任何一个可能有取代基;X代表NH、S或O;环A代表苯环或吡啶环,可能有取代基;1表示1或2的整数;m表示1或2的整数;n表示1到6的整数)。该方法能够以工业上有用的方式合成环状二胺化合物(3)或其盐,其作为ACAT抑制剂。
  • METHOD FOR PRODUCING CYCLIC DIAMINE DERIVATIVE OR SALT THEREOF
    申请人:Kowa Co., Ltd.
    公开号:EP1627875B1
    公开(公告)日:2013-07-31
  • Madsen, Peter; Knudsen, Lotte B.; Wiberg, Finn C., Journal of Medicinal Chemistry, 1998, vol. 41, # 26, p. 5150 - 5157
    作者:Madsen, Peter、Knudsen, Lotte B.、Wiberg, Finn C.、Carr, Richard D.
    DOI:——
    日期:——
查看更多